Source: International Congress 2017 – Hospital-acquired infections: from prevention to treatment
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
L. Palmer (Stony Brook, United States of America). Eradication of MRSA ventilator-associated infection with inhaled vancomycin.. 4655

Member's Comments

No comment yet.

Related content which might interest you: Ventilator-associated pneumonia due to colistin susceptible-only microorganisms Source: Eur Respir J 2007; 30: 307-313 Year: 2007 Antibiotic treatment for nosocomial pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211 Year: 2004 New antibiotics for VAP Source: Eur Respir Mon 2011; 53: 48-53 Year: 2011 Aerosolised treatment for VAP Source: Eur Respir Mon 2011; 53: 54-65 Year: 2011 Treatment of nosocomial pneumonia with piperacillin-tazobactam Source: Eur Respir J 2007; 30: Suppl. 51, 53s Year: 2007 Community-acquired pneumonia outbreaks control with azithromycin Source: Eur Respir J 2003; 22: Suppl. 45, 148s Year: 2003 Antibiotic resistance and nosocomial pneumonia Source: Eur Respir J 2005; 26: Suppl. 49, 641s Year: 2005 Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia Source: Eur Respir Rev 2007; 16: 45-49 Year: 2007 Nebulised colistin for ventilator-associated pneumonia prevention Source: Eur Respir J 2015; 46: 1732-1739 Year: 2015 Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 33-39 Year: 2007 Efficacy and safety of azithromycin vs. clarithromycin for the treatment of community-acquired pneumonia due to legionella pneumophila Source: Annual Congress 2004 - Community acquired pneumonia - epidemiology and host defence Year: 2004 MRSA as a cause of lung infection including airway infection, community-acquired pneumonia and hospital-acquired pneumonia Source: Eur Respir J 2009; 34: 1470-1476 Year: 2009 Eradication treatment in Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017 Aetiopathogenesis of VAP revisited Source: Eur Respir Mon 2011; 53: 1-10 Year: 2011 MRSA as a cause of community-acquired pneumonia Source: Eur Respir J 2009; 34: 1013-1014 Year: 2009 VAP: approach to therapy Source: Eur Respir Mon 2011; 53: 36-47 Year: 2011 Levofloxacin non-susceptible streptococcus pneumoniae in community-acquired respiratory infection; prevalence and risk factors Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 Tigecycline vs levofloxacin for the treatment of community-acquired pneumonia (CAP): EU experience Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review Source: Eur Respir J 2008; 31: 625-632 Year: 2008